Biomea Fusion Reports Fourth Quarter and Full Year 2022 Fina

Expanded clinical development footprint of BMF-219, the company’s lead investigational, orally administered, covalent menin inhibitor, to eight liquid and solid tumor indications and type 2... | March 28, 2023

Related Keywords

Canada , Thomas Butler , Biomea Fusion Inc , Exchange Commission , Development Rd Expenses , Securities Exchange , Company Nasdaq , Recent Clinical , Regulatory Highlights , Genetically Defined Liquid Tumors , Mutant Solid Tumors , Acute Leukemias , Investigational New Drug , System Discovery Platform , Cash Equivalents , Restricted Cash , Securities Act , Securities Exchange Act , Exchange Act , Biomea Fusion , Nc Stock Exchange , News , Information , Press Release , Xpanded , Linical , Development , Footprint , F , The , Head , Rally , Covalent , Jenin , O , Flight , Liquid , End , Olid , Humor , Indications , Ype Bmea Us09077a1060 ,